TABLE 6.
Clinical success rate at test of cure for typical pretherapy pathogensa
| Patient group or pathogen | No. of successes/no. in group (% successes)
|
|||
|---|---|---|---|---|
| Bacteriology ITT population
|
Bacteriology PP population
|
|||
| 2,000/125 mg | 875/125 mg | 2,000/125 mg | 875/125 mg | |
| Patients with at least one typical pathogen | 87 | 73 | 67 | 51 |
| S. pneumoniaeb | 32/33 (97.0) | 19/28 (67.9) | 26/27 (96.3) | 16/19 (84.2) |
| H. influenzae | 17/20 (85.0) | 12/13 (92.3) | 14/16 (87.5) | 10/10 (100) |
| Methicillin-susceptible | 15/16 (93.8) | 12/18 (66.7) | 11/11 (100) | 11/13 (84.6) |
| Staphylococcus aureus | ||||
| M. catarrhalis | 3/4 (75.0) | 3/3 (100) | 1/2 (50.0) | 2/2 (100) |
a
See Table 3, footnote a.
b
There were 33 S. pneumoniae isolates from 31 patients with this pathogen in the amoxicillin-clavulanate 2,000/125 mg group; there were 28 S. pneumoniae isolates from 27 patients with the pathogen in the amoxicillin-clavulanate 875/125 mg group.